| 5.56 -0.31 (-5.28%) | 12-15 15:59 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.6 | 1-year : | 8.57 |
| Resists | First : | 6.51 | Second : | 7.34 |
| Pivot price | 6.17  |
|||
| Supports | First : | 5.17 | Second : | 4.3 |
| MAs | MA(5) : | 5.79 |
MA(20) : | 6.21  |
| MA(100) : | 6.56 |
MA(250) : | 0 | |
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 26 |
D(3) : | 29.6 |
| RSI | RSI(14): 42.8 |
|||
| 52-week | High : | 51 | Low : | 4.55 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ABP ] has closed above bottom band by 18.2%. Bollinger Bands are 20.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 6.12 - 6.16 | 6.16 - 6.18 |
| Low: | 5.48 - 5.52 | 5.52 - 5.55 |
| Close: | 5.5 - 5.57 | 5.57 - 5.61 |
Mon, 15 Dec 2025
Abpro Holdings submits IND application for Phase 1 trial of ABP102/CT-P72 - TipRanks
Mon, 15 Dec 2025
Abpro Holdings Submits IND Application for Cancer Drug - TipRanks
Mon, 15 Dec 2025
Abpro Holdings, Inc. Submits IND for Phase 1 Trial of ABP-102/CT-P72 - TradingView — Track All Markets
Mon, 15 Dec 2025
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Mon, 15 Dec 2025
Abpro (Nasdaq: ABP) submits IND for ABP-102/CT-P72 phase 1 HER2+ cancer trial - Stock Titan
Mon, 15 Dec 2025
Abpro Holdings Announces Submission of an IND Application - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 3 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 34.9 (%) |
| Held by Institutions | 2.9 (%) |
| Shares Short | 33 (K) |
| Shares Short P.Month | 71 (K) |
| EPS | -8.25 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -6.04 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -229.6 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0.55 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.42 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -9 (M) |
| Levered Free Cash Flow | 6 (M) |
| PE Ratio | -0.68 |
| PEG Ratio | 0 |
| Price to Book value | -0.93 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.65 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|